NCT06187376撤回2 期
Evaluating the Safety and Acceptability of Using Chinese Herbal Medicine in Patients With Primary Dysmenorrhea: A Randomized-controlled Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Presence or absence of any adverse events
研究概览
简要总结
This is a prospective randomized-controlled trial looking at the safety and acceptability of using Chinese herbal medicine in patients with primary dysmenorrhea. The research team hopes to enroll 100 patients, 50 of whom will be randomized to receive the herbal tincture and 50 who will receive a placebo tincture. Patients will be enrolled and using the assigned tincture for twelve weeks. The research team will assess safety as a primary outcome by the presence or absence of adverse events related to study protocol during the period of participation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 36 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female aged 18-36 are met:
- •Self-reported pain or discomfort during menstruation, as indicated by Grade 1 or higher on the verbal multidimensional scoring system
- •May experience regular menstrual cycle and period must be <7 days in duration
- •May be on birth control
- •Must know or can estimate the date of the next cycle/period
- •May find blood clots in menstrual blood
- •Must be in good health (doesn't report any medical conditions asked in the screening questionnaire)
- •Following a stable, consistent diet regimen
- •Follow a stable, consistent exercise regimen and are willing, for the duration of the study, to not decrease or increase the amount of exercise in their regimen
- •Agree to refrain from any lifestyle changes that may affect their menstrual cycle for the duration of the study (for example, getting on or off hormonal birth control, reducing the amount of exercise)
- •Follow a stable consistent regimen when using any other interventions, such as massage, chiropractic medicine, or acupuncture; agree not to increase or decrease the number of their other interventions
- •Willingness to adhere to the dietary supplement regimen
- •Willingness to refrain from any other dietary supplements targeting the menstrual cycle during the study period
- •Is able to communicate in English
- •Is willing and able to share feedback via REDCap
- •Must provide written informed consent (ICF)
排除标准
- •Do not experience a menstrual cycle
- •Cannot estimate the onset of their next menstrual cycle
- •Do not experience menstrual pain or cramping
- •Follow an extreme diet intervention
- •Experienced severe weight loss in the past 3 months prior to study participation
- •If currently taking allowed supplements, the dosage needs to remain the same throughout the entirety of the study
- •Food intolerances/allergies that require an EpiPen
- •Known allergic reaction to any of the test product ingredients
- •Currently pregnant, want to become pregnant for the duration of the study, or who are breastfeeding
- •Previous users of Elix Cycle Balance
- •Having more than 3 alcoholic drinks a day
- •Have been diagnosed with the following conditions: PCOS, endometriosis, PMDD, adenomyosis, Hashimoto's, anorexia, bulimia, orthorexia, binge eating, any other eating disorder
- •Not been on a stable dose of birth control for the past 6 months
研究组 & 干预措施
Chinese Herbal Medicine (CHM) herbal tincture
Experimental
Chinese herbal tincture
干预措施: Chinese Herbal Medicine (CHM) supplement (Drug)
Placebo
Placebo Comparator
Matching placebo tincture.
干预措施: Placebo (Drug)
结局指标
主要结局
Presence or absence of any adverse events
时间窗: up to 3 months
Presence or absence of any adverse events related to the study protocol during the time of participation.
次要结局
- Dysmenorrhea Symptom Interference (DSI) Scale(up to 3 months)
研究者
Jenny Tang
Assistant Professor
Icahn School of Medicine at Mount Sinai
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) PatientsNon-small Cell Lung Cancer (NSCLC)NCT03407300Haining Health-Coming Biotech Co., Ltd.80
已完成
不适用
R U OK? The Acceptability and Feasibility of New Communication Technologies for Follow-up After Medical AbortionLegally Induced Abortion, Complete, Without Mention of ComplicationNCT01362387Gynuity Health Projects999
Enrolling By Invitation
4 期
A Study for Post op Inflammation After Cataract SurgeryCataractNCT05665270Wyse Eyecare40
Unknown
4 期
A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal FibrosisIdiopathic Retroperitoneal FibrosisNCT04762810Peking Union Medical College Hospital40
已完成
不适用
Safety of Cell-free Adipose Tissue Product in Healthy VolunteersSafety IssuesNCT05518084Linio Biotech Oy38